Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, has today purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 66 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 798,946 […]

Advanced Oncotherapy (AVO) – Significant Shareholder Dealing

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that AB Segulah, a significant shareholder of the Company, today purchased 150,000 ordinary shares of 25 pence each in the Company at a price of 66 pence per Ordinary Share. Following this transaction, AB Segulah now holds 3,219,451 Ordinary Shares representing […]

Advanced Oncotherapy (AVO) – Additional director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 59.75 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 773,946 Ordinary Shares […]

Advanced Oncotherapy (AVO) – Further progress in the technical development of the LIGHT system

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has integrated the proton source and Radio Frequency Quadruple (RFQ), following a successful testing and calibration programme at ADAM, in Geneva. This work has demonstrated there is a predicted acceleration of the proton beam through this very […]

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased a further 25,000 ordinary shares of 25 pence each in the Company at a price of 56 pence per Ordinary Share. Following this transaction, Dr Vanni now holds […]

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 55 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 723,946 Ordinary […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 50 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 698,946 Ordinary […]

Advanced Oncotherapy (AVO) – Video of LIGHT system and testing facilities

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a new video is available on the Company’s website providing an inside look at the groundbreaking technical development of the LIGHT system at its testing facility on the CERN campus in Geneva. The video can be viewed here: www.avoplc.com […]